High Dose Trial in COPD

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2005
The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients with COPD.
Epistemonikos ID: 0e6d87989feb05995b9af01828bfbf3ffa83812e
First added on: May 04, 2024